Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
| Market Cap | Shares Float | Float Held by Institutions % | Shares Outstanding | Shares Authorized | Institutional Own % |
|---|---|---|---|---|---|
| 5.02 M | 10.03 M | 1.30% | 10.04 M | 20.06 M | 1.30% |
| Date of Short Interest by FINRA | Shares Sold Short | Short Float % | Insider Own % | Number Institutions Holding Shares | MVPHS |
|---|---|---|---|---|---|
| 31-Aug-2023 | 0.02 M | 0.25% | 0.13% | 19 | $7.32 M |
Stock lockup periods can impact investments by potentially causing increased demand and price appreciation during the lockup period, or increased supply and decreased demand when the lockup ends.
| Financial Doc Link | Date of Doc | Cash Equivalents | Burn Rate Operating Activities (monthly) | Operating Expenses (monthly) | Estimated Months Left of Cash |
|---|---|---|---|---|---|
| 10-Q | 15-May-2023 | $10.27 M | $0.72 M | $0.95 M | 0.00 |
| Current Assets | Current Liabilities | Working Capital | Total Assets | Total Liabilities | Total Revenues (12 mo) |
|---|---|---|---|---|---|
| $10.72 M | $11.38 M | -$0.65 M | $11.10 M | $14.49 M | $1.00 M |
Dilutive convertible shares can impact a stock's price by increasing the number of outstanding shares, potentially reducing the value of existing shares and decreasing the stock price.
Stock Warrants can increase share count when exercised. This dilutions affects earnings per share and potentially reduces stock value and impacting investments.
Shelf Registrations can impact a stock's price by increasing the supply of shares available for sale, potentially lowering demand and decreasing stock price, leading to decreased returns on investors.
Shelf Registrations can impact a stock's price by increasing the supply of shares available for sale, potentially lowering demand and decreasing stock price, leading to decreased returns on investors.
Sign up to see if this company has any shelf registrations pending effect
Registration Statements, which provide information on a company's financials and business plans before a public offering, can impact trading by affecting investor perception and demand for the stock, potentially leading to price changes.
Sign up to see if this company has any registration statements
Registration Statements, which provide information on a company's financials and business plans before a public offering, can impact trading by affecting investor perception and demand for the stock, potentially leading to price changes.
Sign up to see if this company has any registration statements pending effect
Company current reports can impact investments by providing important information on material events and changes at the company, affecting the stock price and potential for gains or losses.
A company not being Nasdaq compliant can impact trading performance by reducing investor confidence and potentially leading to decreased demand, lower stock price, and decreased liquidity in the market.